The ultimate test of specificity is to insert a gene construct with a point mutation that cannot be knocked down by the siRNA and show that it rescues the phenotype induced by the siRNA.” ...

A Phase 1 trial testing RAG-17, a potential ALS therapy for people carrying SOD1 mutations, has dosed its first participant.

Ractigen Therapeutics has dosed the first subject in the randomised Phase I clinical trial of its small interfering RNA ...

utilizing RNAi to silence KRAS mutations at the genetic level. Its Local Drug EluteR (LODER™) platform bypasses the tumor microenvironment’s barriers, delivering siRNA directly into the tumor ...

Through this existing collaboration, Evonik’s proprietary biodegradable long-acting PLGA microparticle formulation was used for SIL-204, Silexion’s next-generation siRNA candidate. This ...

Through this existing collaboration, Evonik’s proprietary biodegradable long-acting PLGA (RESOMER ®) microparticle formulation was used for SIL-204, Silexion’s next-generation siRNA candidate.

Individuals who have a protective loss-of-function mutation in the INHBE gene have a healthier cardiometabolic profile ... In ...

Ractigen Therapeutics begins patient dosing in phase I trial of RAG-17 in SOD1-ALS: Nantong, China Friday, December 27, 2024, 12:00 Hrs [IST] Ractigen Therapeutics, a clinical-sta ...

Silexion’s next-generation siRNA candidate. This innovative formulation has demonstrated high efficacy in preclinical models using mice with human pancreatic tumor cell lines carrying various KRAS ...